Akebia Therapeutics (AKBA) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Akebia Therapeutics AKBA is currently developing the following drugs: Praliciguat, Vadadustat, Erythropoiesis-Stimulating Agent, Vadadustat, Vadadustat, Mircera, Vadadustat, Darbepoetin Alfa, Vadadustat, Sevelamer Carbonate, Calcium Acetate, Auryxia, Epoetin Alfa, Vadadustat, Darbepoetin Alfa, Rosuvastatin, Atorvastatin, Simvastatin, Sulfasalazine, Pravastatin, Vadadustat, Digoxin, Vadadustat, Furosemide, Adefovir, Vadadustat, Rabeprazole, Rifampin, Probenecid, Vadadustat, Cyclosporins, Epoetin Alfa, Vadadustat, Vadadustat Tiw, Vadadustat Reference Tablets, Vadadustat Test Tablets, Iw-1973, Epoetin Alfa, Vadadustat, Celecoxib, Akb-6548, Akb-6548 Tablet, Reference Formulation Given In The Fasted State, Akb-6548 Tablet, Test Formulation Given In The Fasted State., Akb-6548 Tablet, Test Formulation Given In The Fed State, Akb-6548, Ferrous Sulfate, Akb-6548, Moxifloxacin, Akb-6548. These drug candidates are in various stages of clinical development as the company works toward FDA approval.